medigraphic.com
Boletín Clínico de la Asociación Médica del Hospital Infantil del Estado de Sonora

2024, Number 2

<< Back Next >>

Bol Clin Hosp Infant Edo Son 2024; 41 (2 )

Approach to hepatomegaly (first part)

Quero HA, Reyes GU, Quero EA, Reyes HKL, Álvarez SR, Juárez VR, López CG, Balderas CX

Language: Spanish
References: 24
Page: 23-29
PDF size: 283.24 Kb.


ABSTRACT

Hepatomegaly is a clinical sign that is relatively frequently identified during the patient’s physical examination. It is rarely a causal finding; it is more likely that they seek medical evaluation due to abdominal symptoms and this finding may represent a sign of liver disease itself or be part of a syndromic complex of other systemic entities, with a great variability in pathophysiological, clinical, treatment and prognostic characteristics. They causes have a different frequency, so in children under 1 year of age it is common for them to describe infectious and metabolic processes. While in older children the infectious cause continues to predominate, followed by neoplastic diseases and storage diseases. The objective of the present review is to propose a diagnostic route for the health professional located at the first and second level of medical care, which allows him to assist in the timely identification and opt for the best treatment for the patient with hepatomegaly.


REFERENCES

  1. Ortega PE, Hoyos GR. Hepatomegalia en la infancia.Form Act Pediatr Aten Prim. 2009; 2(4): 202-7.

  2. Loredo AA, Mata QLC, Carbajal RL, Villaseñor ZJ.Hepatoesplenomegalia de etiología desconocida:abordaje clínico para su diagnóstico en 57 casos.Bol Med Hosp Infant Mex. 1989; 46(1): 41-6.

  3. Sotelo CN. Hepatoesplenomegalia de origen desconocido.E studio de 63 c asos. Gac Med M ex.1991; 127(4): 321-6.

  4. Pérez LA, Moneada W. Perfil epidemiológico delniño con hepatoesplenomegalia. Honduras Pediátrica.2006; 26(3): 5-9.

  5. Zarate Vergara A, Castro Salas U, Tirado Pérez I.Generalidades de un paciente afebril con hepatoesplenomegaliaen pediatria. Revista PediatríaElectrónica. 2020; 17(2): 39-45.

  6. Cofré F, Delpiano L, Yenis L, Reyes A, Izquierdo G.Síndrome de TORCH: enfoque racional del diag-nóstico y tratamiento pre y posnatal. Recomendacionesdel comité Consultivo de Infecciones NeonatalesSociedad Chilena de Infectología, 2016.Rev Chilena Infectol. 2016; 33(2): 191-216.

  7. Neu N, Duchon J, Zachariah P. TORCH infectios.Clin Perinatal. 2015; 42(1): 77-103. doi:10.1016/j.clp.2014.11.001

  8. González Amores Y, Casado Bernabeu A, GarcíaCortéz M, Gómez Navarro E. Afectación hepáticaem las enfermidades sistémicas. RAPD ONLINE.2018; 41(4): 193-203.

  9. Seema Alam, Bikrant Bihari Lal. Metabolic liver diseasespresenting as acute liver failure in children.Indian Pediatr. 2016; 8(53): 695-701. doi: 10.1007/s13312-016-0913

  10. Janani S, Rodríguez V, Eapen KJ, Justin DK, RonaldS. Autoinmmune hemolytic anemia in children:mayo clinic experience. J Pediatr HematolOncol. 2016; 38(3): el20-4.

  11. Risinger M, Emberesh M, Kalfa TA. Rare hereditaryhemolytic anemias: diagnostic approachconsiderations in management. Hematol OncolClin North Am. 2019; 33(3): 373-92. doi: 10.1016/j.hoc.2019.01.002

  12. Ozen H. Glycogen storage diseases: new perspectives.World J Gastroenterol. 2007; 13(18): 2541-53.

  13. Stirnemann J, Belmatoug N, Camou F, SerratriceCh, Froissart R. A review of gaucher disease pathophysilogy,clinical presentation and treatments.Int J M ol S ci. 2 017; 1 8(2): 4 41-71. d oi: 1 0.3390/ijms18020441

  14. Venkatramani R, Spector GL, Giorgieff M, TomilsonG, Krailo M, Mologolowkin M, et al. Congenitalabnormalities and hepatoblastoma: a report fromthe Children´s Oncology Group (COG) and the Utahpopulation database (UPDB). Am J Med Genet.2014; 164(9): 2250-5. doi: 10.1002/ajmg.a.3663

  15. Ortega Paez E, Hoyos Gurrea R. Hepatomegalia enla infancia. Form Act Pediatr Aten Prim. 2009; 2(4):202-207.

  16. Allen RW, Whittle BS, Rainusso N. Pediatric solidtumors in children and adolescents: an overview.Pediatr Rev. 2018; 39(9): 444-53. doi: 10.1542/pir.2017-0268

  17. Bezerra AJ, Wells GR, Mack LC, Karpen JS, HoofnagleJH, et al. Biliary atresia: clinical and researchchallenges for the twenty-first century. Hepatology.2018; 68(3): 1163-73. doi: 10.1002/hep.29905

  18. Expósito de Mena H, Torres Peral R. Guía de algoritmosen Pediatría de Atención Primaria. Hepatomegalia.AEPap; 2016.

  19. Muñoz BG. Hepatomegalia. Pediatr Integral. 2015;3: 180-97.

  20. Chinsky MJ, Singh R, Ficicioglu C, Clara DM, KarnebeekV, Grompe M, Grant Mitchell, et al. Diagnosisand treatment of tyrosinemia type I: a US andCanadian consensus group review and recommendations.Genet Med. 2017; 19(12). doi: 10.1038/gim.2017.101

  21. Marinos P, Kelly C, Wang T, Livingstone C, AlaA. Wolman´s disease and cholesteryl ester storagedisorder: the phenotypic spectrum of lysosomalacid lipase deficiency. Lancet Gastroenterol Hepatol.2017; 2(9): 670-9.

  22. Siu Ying AN, Kam Lun Hon, Wing Kwan AL, LeungA, Choi P. Hemangiomatosis: propranolol beyondinfantile hemangioma. Case Rep Pediatr.2016:9803975. Doi:10.1155/2016/9803975

  23. Pappo SP, Furman LW, Schultz AK, Ferrari A, HelmanL, Krailo DM. Rare tumors in children: progressthrough collaboration. J Clin Oncol. 2015;33: 3047-3054.

  24. De Mena HE, Torres PR. Guía de algoritmos enPediatría de Atención Primaria. Hepatomegalia.AEPap; 2016 (En línea). Disponible en: algoritmos.aepap.org




2020     |     www.medigraphic.com